These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 23540718

  • 1. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y.
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
    Mariano C, Bosdet I, Karsan A, Ionescu D, Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S, Ho C.
    Lung Cancer; 2014 Jan; 83(1):73-7. PubMed ID: 24192511
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [Abstract] [Full Text] [Related]

  • 6. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M.
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [Abstract] [Full Text] [Related]

  • 7. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 8. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
    Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):232-43. PubMed ID: 22897752
    [Abstract] [Full Text] [Related]

  • 9. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
    Takahashi K, Saito H, Hasegawa Y, Ando M, Yamamoto M, Kojima E, Sugino Y, Kimura T, Nomura F, Ogasawara T, Shindoh J, Yoshida N, Suzuki R.
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M.
    J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
    [Abstract] [Full Text] [Related]

  • 12. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
    Choi YJ, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn JH, Kim SW.
    BMC Cancer; 2015 Oct 22; 15():763. PubMed ID: 26493267
    [Abstract] [Full Text] [Related]

  • 15. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
    Ku GY, Haaland BA, de Lima Lopes G.
    Lung Cancer; 2011 Dec 22; 74(3):469-73. PubMed ID: 21565418
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T.
    Lung Cancer; 2015 May 22; 88(2):181-6. PubMed ID: 25726043
    [Abstract] [Full Text] [Related]

  • 17. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.
    Lung Cancer; 2011 Mar 22; 71(3):249-57. PubMed ID: 21216486
    [Abstract] [Full Text] [Related]

  • 18. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X, Han B, Gu A, Zhang Y, Jiao SC, Wang CL, He J, Jia X, Zhang L, Peng J, Wu M, Ying K, Wang J, Ma K, Zhang S, You C, Tan F, Wang Y, Ding L, Sun Y.
    Lung Cancer; 2014 Nov 22; 86(2):207-12. PubMed ID: 25261231
    [Abstract] [Full Text] [Related]

  • 19. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.
    Anticancer Res; 2013 Nov 20; 33(11):5057-64. PubMed ID: 24222150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.